AU2018312349A1 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors - Google Patents
Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors Download PDFInfo
- Publication number
- AU2018312349A1 AU2018312349A1 AU2018312349A AU2018312349A AU2018312349A1 AU 2018312349 A1 AU2018312349 A1 AU 2018312349A1 AU 2018312349 A AU2018312349 A AU 2018312349A AU 2018312349 A AU2018312349 A AU 2018312349A AU 2018312349 A1 AU2018312349 A1 AU 2018312349A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- compound
- mmol
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CC1=CCCC1 Chemical compound *CC1=CCCC1 0.000 description 17
- JXFDEOWBGDMXLM-UHFFFAOYSA-N CC(C)(C)OC(N1CC(COc2nc(Cl)nc3c2cn[n]3C2OCCCC2)C1)=O Chemical compound CC(C)(C)OC(N1CC(COc2nc(Cl)nc3c2cn[n]3C2OCCCC2)C1)=O JXFDEOWBGDMXLM-UHFFFAOYSA-N 0.000 description 2
- RFUQMXWOVPSHLC-QGZVFWFLSA-N Oc(cc1)ccc1-c1cc(NC([C@@H]2OCCNC2)=O)c(cn[nH]2)c2c1 Chemical compound Oc(cc1)ccc1-c1cc(NC([C@@H]2OCCNC2)=O)c(cn[nH]2)c2c1 RFUQMXWOVPSHLC-QGZVFWFLSA-N 0.000 description 2
- OLAQLTWAYVSNQI-LJQANCHMSA-N C=CC(N1C[C@H](C(Nc2c(cn[nH]3)c3cc(-c(cc3)ccc3O)c2)=O)OCC1)=O Chemical compound C=CC(N1C[C@H](C(Nc2c(cn[nH]3)c3cc(-c(cc3)ccc3O)c2)=O)OCC1)=O OLAQLTWAYVSNQI-LJQANCHMSA-N 0.000 description 1
- WOLOIWOQNPHRMW-DJZRFWRSSA-N CC(C)(C)OC(N(CC1)C[C@H]1Oc1c(cn[n]2C3OCCCC3)c2cc(C)c1)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1Oc1c(cn[n]2C3OCCCC3)c2cc(C)c1)=O WOLOIWOQNPHRMW-DJZRFWRSSA-N 0.000 description 1
- QZVCJLUVFPPQLX-ZETCQYMHSA-N CC(C)(C)OC(N(CC1)C[C@H]1S)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1S)=O QZVCJLUVFPPQLX-ZETCQYMHSA-N 0.000 description 1
- HXRDRJKAEYHOBB-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CO)C1)=O Chemical compound CC(C)(C)OC(N1CC(CO)C1)=O HXRDRJKAEYHOBB-UHFFFAOYSA-N 0.000 description 1
- NVTSEFRTGBBFLQ-IDCGIGBZSA-N CC(C)(C)OC(N1C[C@H](C(Nc2c(cn[n]3C4OCCCC4)c3cc(-c(cc3)ccc3O[Si+](C)(C)C(C)(C)C)c2)=O)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](C(Nc2c(cn[n]3C4OCCCC4)c3cc(-c(cc3)ccc3O[Si+](C)(C)C(C)(C)C)c2)=O)OCC1)=O NVTSEFRTGBBFLQ-IDCGIGBZSA-N 0.000 description 1
- NSRUABQFDXEAKD-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)Oc(cc1)ccc1-c1cc(N)c(cn[n]2C3OCCCC3)c2c1 Chemical compound CC(C)(C)[Si+](C)(C)Oc(cc1)ccc1-c1cc(N)c(cn[n]2C3OCCCC3)c2c1 NSRUABQFDXEAKD-UHFFFAOYSA-N 0.000 description 1
- PXRZJPZLANBDEE-UHFFFAOYSA-N CC1(CCNCC1)Oc1c(cn[nH]2)c2cc(-c(cc2)ccc2O)c1 Chemical compound CC1(CCNCC1)Oc1c(cn[nH]2)c2cc(-c(cc2)ccc2O)c1 PXRZJPZLANBDEE-UHFFFAOYSA-N 0.000 description 1
- YXPWZTOAXPIENE-UHFFFAOYSA-N CCCC1=C(C)CCC1 Chemical compound CCCC1=C(C)CCC1 YXPWZTOAXPIENE-UHFFFAOYSA-N 0.000 description 1
- NFQYQLCCUGLALS-XCODYQFDSA-N CCOC(/C=C/[C@@H]1N(C)CCC1)=O Chemical compound CCOC(/C=C/[C@@H]1N(C)CCC1)=O NFQYQLCCUGLALS-XCODYQFDSA-N 0.000 description 1
- HWYPNSNTWWBBPP-ONEGZZNKSA-N CN(C)C/C=C/C(N(C1)CC1(COc1c(cn[nH]2)c2cc(-c(cc2F)ccc2O)c1)C#N)=O Chemical compound CN(C)C/C=C/C(N(C1)CC1(COc1c(cn[nH]2)c2cc(-c(cc2F)ccc2O)c1)C#N)=O HWYPNSNTWWBBPP-ONEGZZNKSA-N 0.000 description 1
- RXWPLFIFFHKQLB-ONEGZZNKSA-N CN(C)C/C=C/C(N1CC(COc2c(cn[nH]3)c3cc(-c(cc3)cc(F)c3O)c2)C1)=O Chemical compound CN(C)C/C=C/C(N1CC(COc2c(cn[nH]3)c3cc(-c(cc3)cc(F)c3O)c2)C1)=O RXWPLFIFFHKQLB-ONEGZZNKSA-N 0.000 description 1
- PSTIRVSWMZOYET-SNAWJCMRSA-N Cc(cc1)ccc1-c1cc(OCC(C2)CN2C(/C=C/CN(C)C)=O)c(cn[nH]2)c2c1 Chemical compound Cc(cc1)ccc1-c1cc(OCC(C2)CN2C(/C=C/CN(C)C)=O)c(cn[nH]2)c2c1 PSTIRVSWMZOYET-SNAWJCMRSA-N 0.000 description 1
- NBJNGIULIYHXSR-UHFFFAOYSA-N Cc(cc1)ccc1-c1cc(OCC(C2)CN2C(C=C)=O)c(cn[nH]2)c2n1 Chemical compound Cc(cc1)ccc1-c1cc(OCC(C2)CN2C(C=C)=O)c(cn[nH]2)c2n1 NBJNGIULIYHXSR-UHFFFAOYSA-N 0.000 description 1
- VEWQMHKFSDEHJR-UHFFFAOYSA-N Cc1nc(Cl)nc2c1cn[n]2C1OCCCC1 Chemical compound Cc1nc(Cl)nc2c1cn[n]2C1OCCCC1 VEWQMHKFSDEHJR-UHFFFAOYSA-N 0.000 description 1
- SIFWVSXAIUVYPQ-UHFFFAOYSA-N OBc(cc1)ccc1O Chemical compound OBc(cc1)ccc1O SIFWVSXAIUVYPQ-UHFFFAOYSA-N 0.000 description 1
- MOFQHACHJXNRTD-NSHDSACASA-N Oc(cc1)ccc1-c1cc(OC[C@@H]2CNCC2)c2nn[nH]c2c1 Chemical compound Oc(cc1)ccc1-c1cc(OC[C@@H]2CNCC2)c2nn[nH]c2c1 MOFQHACHJXNRTD-NSHDSACASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539642P | 2017-08-01 | 2017-08-01 | |
| US62/539,642 | 2017-08-01 | ||
| PCT/US2018/044508 WO2019027960A1 (en) | 2017-08-01 | 2018-07-31 | BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018312349A1 true AU2018312349A1 (en) | 2020-02-06 |
Family
ID=63209687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018312349A Abandoned AU2018312349A1 (en) | 2017-08-01 | 2018-07-31 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10392368B2 (enExample) |
| EP (1) | EP3652169A1 (enExample) |
| JP (2) | JP7098716B2 (enExample) |
| KR (1) | KR20200036004A (enExample) |
| CN (1) | CN111032646B (enExample) |
| AR (1) | AR112348A1 (enExample) |
| AU (1) | AU2018312349A1 (enExample) |
| BR (1) | BR112020002265A2 (enExample) |
| CA (1) | CA3069990A1 (enExample) |
| CL (1) | CL2020000283A1 (enExample) |
| CO (1) | CO2020001469A2 (enExample) |
| EA (1) | EA038912B1 (enExample) |
| IL (1) | IL272031A (enExample) |
| MA (1) | MA49570A (enExample) |
| MX (1) | MX2020001170A (enExample) |
| MY (1) | MY200629A (enExample) |
| PE (1) | PE20201028A1 (enExample) |
| PH (1) | PH12020500201A1 (enExample) |
| SG (1) | SG11202000602YA (enExample) |
| TW (1) | TW201920150A (enExample) |
| UA (1) | UA125318C2 (enExample) |
| WO (1) | WO2019027960A1 (enExample) |
| ZA (1) | ZA202000561B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200036004A (ko) | 2017-08-01 | 2020-04-06 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물 |
| CN113498352A (zh) * | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| CN114126618A (zh) * | 2019-07-15 | 2022-03-01 | 诺华股份有限公司 | 用肝脏x受体激动剂治疗睑板腺功能障碍的方法 |
| CA3179566A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof |
| JP2023528239A (ja) * | 2020-05-14 | 2023-07-04 | テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー | 腸管選択的ｊａｋ３阻害剤の投与 |
| CN114075220A (zh) * | 2020-08-13 | 2022-02-22 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| WO2022033544A1 (zh) * | 2020-08-13 | 2022-02-17 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| WO2022053000A1 (zh) * | 2020-09-10 | 2022-03-17 | 四川海思科制药有限公司 | 一种碳环酰胺衍生物及其在医药上的应用 |
| WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
| KR20230163469A (ko) * | 2021-03-29 | 2023-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태 |
| CN113061137B (zh) * | 2021-04-02 | 2022-08-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
| US12268667B2 (en) * | 2021-05-03 | 2025-04-08 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of prurigo nodularis |
| US20250051360A1 (en) * | 2021-12-23 | 2025-02-13 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compound, and composition and use thereof |
| WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004526781A (ja) | 2001-04-20 | 2004-09-02 | ワイス | ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルアルコキシ−、−アルキルチオ−および−アルキルアミノベンザゾール誘導体 |
| FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| PT1638941E (pt) | 2003-05-22 | 2010-08-24 | Abbott Lab | Inibidores de quinases de indazole, benzisoxazole e benzisotiazole |
| EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
| WO2007050574A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| EP1999135A2 (en) | 2006-03-30 | 2008-12-10 | Takeda San Diego, Inc. | Kinase inhibitors |
| KR100834758B1 (ko) | 2006-07-05 | 2008-06-05 | 삼성전자주식회사 | 컴퓨터 시스템 보안 장치 및 방법 |
| JP2009007342A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
| EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
| JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
| JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| HUE045869T2 (hu) | 2010-11-02 | 2020-01-28 | Univ Columbia | Módszerek hajhullásos rendellenességek kezelésére |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物 |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| HRP20181976T1 (hr) | 2012-03-29 | 2019-01-25 | The Trustees Of Columbia University In The City Of New York | Postupci za liječenje poremećaja gubitka kose |
| WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| TWI629275B (zh) | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体 |
| WO2015083028A1 (en) | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| EP3097091A1 (en) | 2014-01-24 | 2016-11-30 | AbbVie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
| CN106661039B (zh) * | 2014-02-28 | 2019-09-13 | 林伯士拉克许米公司 | 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途 |
| TN2016000503A1 (en) | 2014-05-14 | 2018-04-04 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
| US10519160B2 (en) | 2014-07-18 | 2019-12-31 | The General Hospital Corporation | Imaging agents for neural flux |
| KR102602947B1 (ko) | 2014-11-03 | 2023-11-16 | 아이오메트 파마 엘티디 | 제약 화합물 |
| CN105837574B (zh) | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
| EP3288943B1 (en) * | 2015-05-01 | 2022-09-28 | Pfizer Inc. | Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase |
| US20180291378A1 (en) | 2015-05-07 | 2018-10-11 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for promoting hair growth |
| EP3865481A1 (en) | 2015-11-03 | 2021-08-18 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| CN109311896B (zh) | 2016-06-30 | 2021-08-24 | 株式会社大熊制药 | 吡唑并嘧啶衍生物作为激酶抑制剂 |
| WO2018049174A1 (en) | 2016-09-08 | 2018-03-15 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
| IL266109B2 (en) | 2016-10-21 | 2025-05-01 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| US20180117148A1 (en) | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR20200036004A (ko) | 2017-08-01 | 2020-04-06 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물 |
| AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| EP3733673B1 (en) | 2017-12-28 | 2022-06-29 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivative as kinase inhibitor |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| CN113498352A (zh) * | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| JP2023528239A (ja) * | 2020-05-14 | 2023-07-04 | テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー | 腸管選択的ｊａｋ３阻害剤の投与 |
-
2018
- 2018-07-31 KR KR1020207005956A patent/KR20200036004A/ko not_active Withdrawn
- 2018-07-31 BR BR112020002265-9A patent/BR112020002265A2/pt not_active Application Discontinuation
- 2018-07-31 WO PCT/US2018/044508 patent/WO2019027960A1/en not_active Ceased
- 2018-07-31 EA EA202090413A patent/EA038912B1/ru unknown
- 2018-07-31 EP EP18755621.2A patent/EP3652169A1/en not_active Withdrawn
- 2018-07-31 PE PE2020000171A patent/PE20201028A1/es unknown
- 2018-07-31 MX MX2020001170A patent/MX2020001170A/es unknown
- 2018-07-31 JP JP2020505224A patent/JP7098716B2/ja active Active
- 2018-07-31 CA CA3069990A patent/CA3069990A1/en not_active Abandoned
- 2018-07-31 AR ARP180102151 patent/AR112348A1/es unknown
- 2018-07-31 AU AU2018312349A patent/AU2018312349A1/en not_active Abandoned
- 2018-07-31 MY MYPI2020000251A patent/MY200629A/en unknown
- 2018-07-31 TW TW107126579A patent/TW201920150A/zh unknown
- 2018-07-31 MA MA049570A patent/MA49570A/fr unknown
- 2018-07-31 SG SG11202000602YA patent/SG11202000602YA/en unknown
- 2018-07-31 CN CN201880050675.3A patent/CN111032646B/zh not_active Expired - Fee Related
- 2018-07-31 US US16/050,227 patent/US10392368B2/en active Active
- 2018-07-31 UA UAA202001352A patent/UA125318C2/uk unknown
-
2019
- 2019-06-28 US US16/456,179 patent/US10538513B2/en active Active
- 2019-11-19 US US16/688,109 patent/US10968205B2/en not_active Expired - Fee Related
-
2020
- 2020-01-14 IL IL272031A patent/IL272031A/en unknown
- 2020-01-27 PH PH12020500201A patent/PH12020500201A1/en unknown
- 2020-01-28 ZA ZA2020/00561A patent/ZA202000561B/en unknown
- 2020-01-31 CL CL2020000283A patent/CL2020000283A1/es unknown
- 2020-02-11 CO CONC2020/0001469A patent/CO2020001469A2/es unknown
-
2021
- 2021-02-22 US US17/249,128 patent/US20220119369A1/en not_active Abandoned
- 2021-03-17 JP JP2021043173A patent/JP2021098751A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190315724A1 (en) | 2019-10-17 |
| EA202090413A1 (ru) | 2020-06-24 |
| PH12020500201A1 (en) | 2020-10-12 |
| EP3652169A1 (en) | 2020-05-20 |
| EA038912B1 (ru) | 2021-11-09 |
| UA125318C2 (uk) | 2022-02-16 |
| SG11202000602YA (en) | 2020-02-27 |
| MY200629A (en) | 2024-01-06 |
| IL272031A (en) | 2020-03-31 |
| TW201920150A (zh) | 2019-06-01 |
| KR20200036004A (ko) | 2020-04-06 |
| US20190040043A1 (en) | 2019-02-07 |
| JP2021098751A (ja) | 2021-07-01 |
| CN111032646A (zh) | 2020-04-17 |
| AR112348A1 (es) | 2019-10-16 |
| MA49570A (fr) | 2020-05-20 |
| PE20201028A1 (es) | 2020-10-05 |
| MX2020001170A (es) | 2020-03-12 |
| US10968205B2 (en) | 2021-04-06 |
| US10538513B2 (en) | 2020-01-21 |
| US20200216423A1 (en) | 2020-07-09 |
| BR112020002265A2 (pt) | 2020-07-28 |
| US20220119369A1 (en) | 2022-04-21 |
| CL2020000283A1 (es) | 2020-06-12 |
| CN111032646B (zh) | 2023-01-03 |
| ZA202000561B (en) | 2022-04-28 |
| JP7098716B2 (ja) | 2022-07-11 |
| JP2020529987A (ja) | 2020-10-15 |
| WO2019027960A1 (en) | 2019-02-07 |
| CA3069990A1 (en) | 2019-02-07 |
| CO2020001469A2 (es) | 2020-05-29 |
| US10392368B2 (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10968205B2 (en) | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | |
| US12358931B2 (en) | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | |
| CA3125039A1 (en) | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors | |
| HK40014855A (en) | Process and intermediates for the preparation of naphthyridine compounds as jak kinase inhibitors | |
| HK1245771B (en) | Naphthyridine compounds as jak kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |